Connect with us

Technology

ImpediMed Secures $15m Growth Capital Funding

Published

on

New round will help fuel commercialization efforts in support of ImpediMed’s platform technology for the detection and monitoring of lymphedema.

CARLSBAD, Calif., Feb. 7, 2025 /PRNewswire/ — ImpediMed, a leader in medical technologies to clinically monitor and manage fluid and body composition, today announced an agreement for a five-year $15 million growth capital facility with SWK Holdings (NASDAQ:SWKH), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies. Funds raised will provide ImpediMed with funding flexibility and will be used to support growth and commercialization activities. Armentum Partners acted as the Company’s exclusive financial advisor on this transaction.

With this new funding in place, ImpediMed’s capital base is well equipped to support the continued execution of its commercial strategy. As a result, the company is better positioned than ever to achieve its long-term goals and create significant value for its shareholders.

As a pioneer in the field of lymphedema detection and monitoring, ImpediMed offers the only FDA-cleared bioimpedance spectroscopy (BIS) technology for the clinical assessment of breast cancer-related lymphedema (BCRL) –– the SOZO® Digital Health Platform. ImpediMed’s platform is broadly accepted and recognized for effective and accurate screening of lymphedema, with U.S. health payors now providing coverage for over 258 million covered lives.

Lymphedema, a common consequence of cancer treatment, is challenging to detect before symptoms appear. ImpediMed’s SOZO® Digital Health Platform uses BIS to identify fluid changes early, enabling intervention before lymphedema becomes a chronic condition. With growing adoption in clinical practice and increasing payor coverage, ImpediMed’s innovative approach is transforming lymphedema management.

In 2024, the National Accreditation Program for Breast Centers (NABPC) updated its accreditation standards to include lymphedema prevention programs utilizing BIS as an evidence-based guideline for managing lymphedema. The NAPBC is a quality program of the American College of Surgeons, and accredited programs must understand, implement, and demonstrate compliance with accreditation standards outlined in Optimal Resources for Breast Care. This recognition further validates BIS as a critical tool in lymphedema management and presents a significant opportunity for ImpediMed to expand its reach, driving broader adoption of the SOZO Digital Health Platform across breast cancer centers nationwide.1

“We are pleased with our agreement with SWK Holdings and the confidence they have shown in ImpediMed, as well as in the future of our SOZO Digital Health Platform,” said Dr. Parmjot Bains, MD, CEO & Managing Director of ImpediMed. “SWK’s proven approach of supporting innovative healthcare companies makes them an ideal partner for us as we pursue our commercial growth strategy over the next five years. We are confident with the business’ direction, and this was reinforced throughout our due diligence process. In conjunction with our existing cash reserves, this facility gives us the time and funding flexibility required to execute on our business plan and fully capitalize on the BCRL opportunity.”

“We believe that the SOZO Digital Health Platform is revolutionizing how clinicians assess and manage fluid and body composition, ultimately improving patient outcomes,” said JD Tamas, Director of Underwriting at SWK Holdings. “We are excited to provide this capital to support ImpediMed’s continued mission to improve the lives of patients by pushing the boundaries of what’s possible in fluid and tissue analysis.”

About SOZO Digital Health Platform

SOZO, the world’s most advanced, non-invasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed’s BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphoedema, provides fluid status for patients living with heart or renal failure, and can be used to monitor and maintain overall health – all on a single device.

About SWK Holdings

SWK Holdings is a life science focused specialty finance company partnering with small- and mid-sized commercial-stage healthcare companies. SWK provides non-dilutive financing to fuel the development and commercialization of lifesaving and life-enhancing medical technologies and products. SWK’s unique financing structures provide flexible financing solutions at an attractive cost of capital to create long-term value for all SWK stakeholders. SWK’s solutions include structured debt, traditional royalty monetization, synthetic royalty transactions, and asset purchases typically ranging in size from $5.0 million to $25.0 million

About Armentum Partners

Armentum Partners is an investment bank dedicated to assisting healthcare and technology companies access non-dilutive capital.   Since the beginning of 2023, Armentum has raised over $3.5 billion for its clients.

About ImpediMed

Founded in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximize patient health. ImpediMed produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2024, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship continue to reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex®, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed’s SaaS subscription-based business.

For more information, visit www.impedimed.com.

1 Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the American College of Surgeons. Content does not reflect the views or interpretations of the American College of Surgeons.

Media Contact:
Jodi Perkins
Amendola Communications, on behalf of ImpediMed
jperkins@acmarketingpr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/impedimed-secures-15m-growth-capital-funding-302371333.html

SOURCE ImpediMed

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Topaz Labs announces its largest single release of AI models in company history with “Next-Gen” launch

Published

on

By

DALLAS, April 28, 2026 /PRNewswire/ — Topaz Labs, the AI image and video enhancement company, has announced four new image enhancement models and two video enhancement models across five applications. The collection of “Next-Gen” models offer powerful sharpening, denoising, and upscaling results to visual content. Image models included are Wonder 3, Denoise Max, Super Focus 3, and High Fidelity 3. For video, Starlight Precise 2.5 and Astra 2 were announced.

The collection of models offers powerful sharpening, denoising, and upscaling results to visual content.

“This is both the largest and most technically advanced set of models we’ve released in the company’s history,” says Eric Yang, CEO, Topaz Labs. “We launched Topaz NeuroStream earlier this year with the goal of enabling local rendering of complex models for more users. Without such technology, the complex, heavyweight AI models in today’s release would have been limited to cloud-only rendering, forcing users to pay per use and be reliant on internet connection. We believe local use is crucial to the future of AI in both professional and consumer use cases, and today’s release is a huge step.” 

Topaz NeuroStream is proprietary technology that reduces VRAM usage by up to 95% and allows exponentially more users on consumer-grade hardware to use AI models locally. A total of six Topaz models are now powered by NeuroStream.

Next-Gen Release Image Models 

Wonder 3: A magical, one-click sharpen, upscale, and denoise model for images.
Denoise Max: New standard for removing noise and grain in images.
Super Focus 3: Next-level sharpening model that brings subjects back from the blur.
High Fidelity 3: The newest model for upscaling high-res inputs like smartphone photos and RAW images.

All image models in this release are available in Topaz Photo desktop application and via API. Wonder 3 and Denoise Max are also available in Express, a web-based tool.

Next-Gen Release Video Models

Starlight Precise 2.5 (Local): Groundbreaking video model that brings out natural visual details with stunning results, with local availability in Topaz Video

Astra 2: The next generation of creative video upscaling that enhances clarity, richness, and visual complexity of videos by adding new detail.

Both highlighted video models are available via cloud rendering in Astra and API. Starlight Precise 2.5 (Local) can be found in the Topaz Video desktop application.

About Topaz Labs
Founded in 2005, Topaz Labs is a leader in AI-powered image and video enhancement. Its technology is used by 1.5 million customers, including 20 of the world’s top 50 companies. Known for industry-leading products like Topaz Photo, Topaz Video, Topaz Gigapixel, Astra and Bloom, the company continues to invest heavily in research and development, advancing the frontiers of imaging technology in collaboration with academic and industry partners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/topaz-labs-announces-its-largest-single-release-of-ai-models-in-company-history-with-next-gen-launch-302756375.html

SOURCE Topaz Labs

Continue Reading

Technology

Dreame Technology Launches the L60 Series, Led by the Flagship L60 Pro Ultra

Published

on

By

New lineup brings industry-leading intelligence and full-home automation to a new generation of robot vacuums

SAN FRANCISCO, April 28, 2026 /PRNewswire/ — Dreame Technology, a leader in smart home innovation, today announced the L60 Series, a new lineup of four robot vacuums engineered for the full range of modern home environments. Built on a shared foundation of premium cleaning performance, intelligent navigation, and hands-free automation, the L60 Series is designed to meet the needs of every kind of household, from compact apartments to multi-story homes, and from single-surface layouts to complex mixed-flooring environments.

“The L60 Series represents exactly what Dreame stands for: powerful, intelligent cleaning that adapts to how people actually live,” said Ana Wang, CEO of Dreame Technology North America. “Whether you have a multi-story home, pets, mixed flooring, or low furniture, there’s an L60 built for your needs. Every model in the lineup delivers the core cleaning experience our customers expect from Dreame.”

Meet the L60 Series

The L60 Series is built around four distinct models, each tailored to a different home profile and cleaning priority:

L60 Pro Ultra — The Ultimate All-in-One. The flagship vacuum is purpose-built for large floor plans, multi-surface transitions, and complex terrain. Features the 3.46-inch ProLeap™ System, 35,000Pa Vormax™ Suction, Dual Omni-Scrub Mopping with Hot Water, and an industry-leading 6,400mAh PowerCore™ Battery.L60 Ultra — Precision Whole-Home Coverage. A balanced high-performer built around Dreame’s latest 2026 sensor technology and a 3.23in (82mm) ultra-thin design for precise navigation in low-light spaces and flawless cleaning under low-profile furniture. Includes AI-Enhanced 3D ToF Vision, 35,000Pa Vormax™ Suction, HyperStream™ Detangling DuoBrush 2.0, SmartDirt™ Detection, Pet-Friendly Care 5.0, and Matter, Apple Watch, and Home Screen Shortcut support.L60 Ultra PE (Performance Edition) — The Intelligent Step-Up. An upgraded everyday performer for homes that need an extra boost on hair pickup, with 30,000Pa Vormax™ Suction, the HyperStream™ Detangling DuoBrush, 3DAdapt™ Obstacle Avoidance, and Smart Pathfinder Technology with 220 object type recognition.L60 Ultra FE (Fine Edition) — The Essential Automated Choice. An entry-level powerhouse delivering the core promise of maintenance-free floor care, with 30,000Pa Vormax™ Suction, TriCut Brush 3.0, Dual Flex Arm Technology, and the full PowerDock™ automation experience.

A Shared Foundation of Premium Performance

Every model in the L60 Series shares a core set of capabilities that set a new baseline for modern robot vacuums, including:

212°F (100°C) ThermoHub™ Mop Self-Cleaning for hygienically clean mop pads after every cycle30,000–35,000Pa Vormax™ Suction across the lineup for powerful pickup on every surfaceDual Flex Arm Technology for adaptive side-brush and mop coverage in corners and along edgesMop Lifting for seamless transitions between hard floors and carpetAutomatic Solution Dispensing for consistent cleaning chemistry without manual refillsThe 8-in-1 PowerDock™ base station, which handles auto-empty, mop washing, hot-air drying, and solution management for truly hands-free operation

L60 Pro Ultra: The Flagship Experience, Redefined for Complex Homes

Leading the lineup is the L60 Pro Ultra, featuring select top-tier specifications optimized for large-scale layouts and complex terrains. It pairs the series’ most capable hardware with Dreame’s most advanced intelligence to deliver a seamless, one-stop cleaning experience that effortlessly tackles stubborn stains across expansive and complex home layouts.

At the heart of the Pro Ultra’s navigation advantage is the 3.46-inch ProLeap™ System, the lineup’s most capable obstacle-crossing system, paired with VersaLift Navigation for cleaning under low-clearance furniture. It is equipped with dual-laser 3D structured light, an AI RGB camera, and LED illumination, enabling it to recognize over 280 types of obstacles — for precise, real-time avoidance in any lighting condition.

The Pro Ultra delivers 35,000Pa Vormax™ Suction alongside the HyperStream™ Detangling DuoBrush, together extracting embedded debris, pet hair, and fine particles from every floor type without tangles or jams. Its Dual Omni-Scrub Mopping with Hot Water system pairs rotating mop pads with a Thermal Mop Pad and ThermoHub™ 212°F (100°C) Mop Self-Cleaning, while the AceClean™ DryBoard minimizes residue — eliminating grease, bacteria, and moisture that cold-water systems simply can’t address. An industry-leading 6,400mAh PowerCore™ Battery provides whole-home coverage on a single charge.

The Pro Ultra’s OmniDirt™ Detection Technology identifies high-soil areas and automatically triggers Mop Rewashing and Floor Remopping for a truly thorough result. Pet-Friendly Care 4.0 adds pet-aware detection and navigation, while Upgraded Intelligent Carpet Cleaning optimizes suction and mop behavior for mixed-flooring homes. Direct Voice Control and app control round out the experience for effortless day-to-day use.

Pricing and Availability

The Dreame L60 Series is available now through the Dreame website and Amazon (L60 Pro Ultra, L60 Ultra, L60 Ultra PE, L60 Ultra FE), with launch-offer pricing through the official website. Customers who purchase on dreametech.com receive a free accessory kit with their order.

L60 Pro Ultra — MSRP $1,399.99 | Launch Offer $1,259.99L60 Ultra — MSRP $1,299.99 | Launch Offer $1,169.99L60 Ultra PE — MSRP $1,099.99 | Launch Offer $879.99L60 Ultra FE — MSRP $999.99 | Launch Offer $749.99

For more information about the L60 Series, visit dreametech.com/pages/l60-series-robot-vacuum.

About Dreame Technology

Established in 2017, Dreame Technology is an innovative consumer product company focused on smart home cleaning appliances with the vision to empower lives through technology. Follow us on Facebook, Instagram, TikTok and Twitter. For more information, please visit https://www.dreametech.com/.

View original content to download multimedia:https://www.prnewswire.com/news-releases/dreame-technology-launches-the-l60-series-led-by-the-flagship-l60-pro-ultra-302756382.html

SOURCE Dreame Technology

Continue Reading

Technology

Vanda Pharmaceuticals announces the publication of “Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis” in NEJM Evidence

Published

on

By

WASHINGTON, April 28, 2026 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled “Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis” in New England Journal of Medicine (NEJM) Evidence1.

The findings of this pivotal phase III study are included in the Biologics License Application (BLA) for imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP), submitted to the U.S. Food and Drug Administration (FDA) with a target action date of December 12, 2026.

References

Smieszek, S. et al. Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis. NEJM Evidence 5, (2026). 

About Imsidolimab

Imsidolimab is a fully humanized IgG4 monoclonal antibody that inhibits IL-36 receptor signaling and is being developed for GPP, a rare orphan indication. Regulatory and patent exclusivity for imsidolimab is expected to extend into the late 2030s. Vanda holds an exclusive global license for the development and commercialization of imsidolimab from AnaptysBio (Nasdaq: ANAB).

About Vanda Pharmaceuticals

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this press release, including, but not limited to statements regarding the anticipated timing of the completion of the FDA’s review of the imsidolimab BLA; Vanda’s plans to seek FDA approval of imsidolimab for the treatment of GPP; and the potential to extend regulatory and patent exclusivity for imsidolimab into the late 2030s, are “forward-looking statements” under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda’s forward-looking statements include, among others, the FDA’s ability to complete its review of, and reach a decision with respect to, the imsidolimab BLA by December 12, 2026; Vanda’s ability to obtain FDA approval of imsidolimab for the treatment of GPP; and Vanda’s ability to satisfy the conditions necessary to extend regulatory and patent exclusivity for imsidolimab into the late 2030s. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized, or even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda’s business and market, particularly those identified in the “Cautionary Note Regarding Forward-Looking Statements”, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Vanda’s most recent Annual Report on Form 10-K, as updated by Vanda’s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com

Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-the-publication-of-efficacy-and-safety-of-imsidolimab-for-generalized-pustular-psoriasis-in-nejm-evidence-302756392.html

SOURCE Vanda Pharmaceuticals Inc.

Continue Reading

Trending